Shares Expected to Begin Trading on Split-Adjusted Basis on November 5, 2024
November 01, 2024 09:00 ET
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) announced today that it will implement a 1-for-50 reverse stock split of the issued...
Qualigen Therapeutics, Inc. Announces management changes.
September 26, 2024 17:10 ET
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) announced on September 23, 2024, Mr. Michael Poirier, notified the board of directors...
Qualigen Therapeutics, Inc. Received Extension from Nasdaq Hearings Panel
September 20, 2024 09:00 ET
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., Sept. 20, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) today announced that on September 11, 2024, the Company received a notice from Nasdaq...
Qualigen Therapeutics, Inc. Announces Closing of $3.47 Million Public Offering
September 06, 2024 16:30 ET
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) today announced the closing of its previously announced public offering of 14,724,058...
Qualigen Therapeutics, Inc. Announces Pricing of $3.46 Million Public Offering
September 05, 2024 09:00 ET
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) today announced the pricing of a public offering of 14,724,058 shares of common stock,...
Qualigen Therapeutics, Inc. Received Nasdaq Notice of a Delisting Determination
May 30, 2024 16:00 ET
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), announced today that on May 23, 2024, it received written notice (the...
Qualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual Meeting
April 10, 2024 08:00 ET
|
Qualigen Therapeutics, Inc.
Poster Includes Preclinical Data on Novel Direct Pan-RAS Inhibitors CARLSBAD, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN)...
Qualigen Therapeutics Provides Corporate Update for Third Quarter and To Date 2023
November 14, 2023 16:30 ET
|
Qualigen Therapeutics, Inc.
Initiated dosing of three patients in first cohort of Phase 1 clinical trial of QN-302 for treatment of advanced or metastatic solid tumorsPhase 1a patient recruitment ongoing; company anticipates...
Poster Highlighting Qualigen Therapeutics' Pan-RAS Inhibitor Platform Presented at AACR Special Conference: Advances in Breast Cancer
October 23, 2023 08:30 ET
|
Qualigen Therapeutics, Inc.
Poster Includes Preclinical Data on Pan-RAS Compounds Demonstrating Inhibition in Breast Cancer Models CARLSBAD, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq:...
Qualigen Therapeutics Presents Scientific Data on QN-302 at AACR Special Conference: Pancreatic Cancer 2023
September 27, 2023 08:30 ET
|
Qualigen Therapeutics, Inc.
Two posters include data on potential clinical biomarkers and transcriptomic data associated with QN-302’s mechanism of action CARLSBAD, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Qualigen...